Treatment of Severe Henoch-Schoenlein Purpura Nephritis in Children
Journal of the Korean Society of Pediatric Nephrology
;
: 10-21, 2010.
Article
in English
| WPRIM
| ID: wpr-19843
ABSTRACT
The overall prognosis of Henoch-Schoenlein purpura (HSP) is favorable, but severe nephritis has a high risk of progression to end stage renal failure. Recent studies emphasize the importance of early treatment in children with severe HSP nephritis, but the treatment of severe HSP nephritis still remains controversial due to the rarity of randomized controlled studies in this field. Nevertheless, several intensive therapies, such as intravenous high-dose methylprednisolone pulse, immunosuppressive/cytotoxic drugs, fibrinolytic therapy, anticoagulants, antiplatelet agent and plasma exchange, have been used in children with severe HSP nephritis. In this review, we focus on the treatment of severe HSP nephritis in children.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma Exchange
/
Prognosis
/
IgA Vasculitis
/
Methylprednisolone
/
Thrombolytic Therapy
/
Renal Insufficiency
/
Anticoagulants
/
Nephritis
Type of study:
Controlled clinical trial
/
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Journal of the Korean Society of Pediatric Nephrology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS